Assessment of the Real-World Safety of Intravitreal Dexamethasone Implant (Ozurdex): Novel Insights From a Comprehensive Pharmacovigilance Analysis Utilizing the FAERS Database

Baseline Characteristics and Outcomes of Patients Treated With Aflibercept 8 mg at Shortened, Maintained, or Extended Dosing Intervals Through 96 Weeks in PHOTON